Is remission in women with idiopathic generalized epilepsy possible without valproate?
Abstract
Aim of study. This study aimed to evaluate changes in prescription practices for treating idiopathic generalized epilepsy (IGE) in women of childbearing age, and to assess how switching from valproate (VPA) affects seizure outcomes. IGE accounts for 15–20% of all epilepsy cases. While VPA is the most effective treatment, its teratogenic risk limits its use in women of reproductive age, leading to recommendations for safer alternatives such as lamotrigine (LTG) and levetiracetam (LEV).
Material and methods. We retrospectively analysed the data from 130 women aged 18–49 diagnosed with IGE from 2000 to 2022.
Results. Of the 107 who used VPA, 44 remained on it until the last follow-up. 74% of participants achieved seizure freedom at some point, and 62% remained seizure-free at the last follow-up. The attempt to switch from VPA to other medications was unsuccessful in 23 (21.5% out of 107) patients due to adverse effects or loss of seizure control. Seizure freedom rates after 12 months were similar between VPA and alternative ASMs like LEV and LTG.
Conclusions and clinical implications. Our study indicates that LEV and LTG are effective alternatives to VPA for many women with IGE. However, some patients still require VPA for optimal seizure control. Further large-scale, randomised studies are needed to confirm these findings.
Keywords: idiopathic generalized epilepsyremissionwomen of childbearing agevalproatelamotriginelevetiracetam
References
- Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022; 63(6): 1475–1499.
- Wężyk K, Słowik A, Bosak M. Predictors of remission in patients with epilepsy. Neurol Neurochir Pol. 2020; 54(5): 434–439.
- European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. https://www.ema.europa.eu/en/documents/referral/valproate-relatedsubstances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate_en.pdf (30.09.2024).
- Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015; 56(7): 1006–1019.
- Battino D, Tomson T, Bonizzoni E, et al. EURAP Collaborators. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol. 2024; 81(5): 481–489.
- Daugaard CA, Pedersen L, Sun Y, et al. Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. JAMA Netw Open. 2020; 3(11): e2025570.
- Toledo M, Mostacci B, Bosak M, et al. Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective. J Neurol. 2021; 268(8): 2735–2748.
- Cerulli Irelli E, Cocchi E, Morano A, et al. Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy. J Neurol Sci. 2020; 415: 116940.
- Cerulli Irelli E, Morano A, Cocchi E, et al. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome. Epilepsia. 2020; 61(1): 107–114.
- Cerulli Irelli E, Cocchi E, Morano A, et al. Women With Epilepsy Treatment Options and Research (WETOR) Study Group. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy. JAMA Neurol. 2023; 80(11): 1174–1181.
- Cerulli Irelli E, Cocchi E, Morano A, et al. for Women with Epilepsy Treatment Options and Research (WETOR) study group. Predictors of Seizure Recurrence in Women With Idiopathic Generalized Epilepsy Who Switch From Valproate to Another Medication. Neurology. 2024; 102(9): e209222.
- Kiiski R, Basnyat P, Raitanen J, et al. Treatment outcomes in women with idiopathic generalized epilepsy. Acta Neurol Scand. 2022; 145(4): 423–433.
- Milano C, Turco F, Pizzanelli C, et al. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study. Epilepsy Behav. 2021; 115: 107706.
- Panayiotopoulos CP. Syndromes of idiopathic generalized epilepsies not recognized by the International League Against Epilepsy. Epilepsia. 2005; 46 Suppl 9: 57–66.
- Atalar AÇ, Şirin NG, Bebek N, et al. Predictors of successful valproate withdrawal in women with epilepsy. Epilepsy Behav. 2021; 119: 107980.
- Tomson T, Battino D, Bonizzoni E, et al. Declining malformation rates with changed antiepileptic drug prescribing. Neurology. 2019; 93(9).
- Vajda FJE, O'Brien TJ, Graham JE, et al. Antiepileptic drug polytherapy in pregnant women with epilepsy. Acta Neurol Scand. 2018; 138(2): 115–121.
- Bosak M, Song BH, Dewerenda-Sikora M, et al. Obstetric and neonatal outcomes in women with epilepsy in Poland - a two-centre study. Neurol Neurochir Pol. 2020; 54(1): 62–65.
- Bosak M, Wężyk K, Słowik A. Lacosamide and myoclonic seizures: what is the risk of aggravation? Neurol Neurochir Pol. 2021; 55(1): 107–109.
- Bosak M, Dziedzic R, Matwiej K, et al. Outcomes following exposure to lacosamide monotherapy during pregnancy and breastfeeding - a prospective case series. Neurol Neurochir Pol. 2024; 58(2): 203–206.
